Soon-Shiong Tightens Grip on ImmunityBio as Stake Climbs to 64.8%
IBRX has more than doubled off its 52-week low of $1.95.
Summary
Patrick Soon-Shiong's beneficial ownership in ImmunityBio increased to 64.8% as of July 31, 2026, per an amended 13D filing, reflecting a tighter grip on the company amid strong revenue growth and ongoing financial risks.
Key Events · Ownership and Investor Activity · IBRX
-
Soon-Shiong Stake Rises to 64.8%
As of July 31, 2026, Patrick Soon-Shiong's aggregate beneficial ownership climbed to 745,518,285 shares, or 64.8% of outstanding common stock, up from prior filings.
-
Nant Capital Holds 29.6% with Note Conversion
Nant Capital, LLC reports 29.6% beneficial ownership, a figure that includes 88,446,655 shares acquirable within 60 days via conversion of a promissory note, adding potential dilution.
-
Affiliated Entities Control Significant Blocks
Substantial stakes are held by Cambridge Equities (24.7%), California Capital Equity (10.0%), and NantWorks (9.3%), all ultimately controlled by Soon-Shiong.
-
Ownership Concentration Amid Financial Crossroads
The increased insider control arrives as ImmunityBio posted record Q2 revenue of $50.7M but also disclosed a going concern warning and $672M in non-cash fair value losses.
Analysis · IBRX · Life Sciences
An amended Schedule 13D shows founder and CEO Patrick Soon-Shiong now beneficially owns 64.8% of ImmunityBio, up from prior levels, consolidating control against a backdrop of record revenue and a going concern warning. The filing details a complex web of affiliated entities holding significant stakes, with Nant Capital's position including 88.4 million shares acquirable via a promissory note conversion. This concentration of ownership reduces public float and could amplify stock volatility, but it also signals the CEO's deep financial commitment as the company navigates its cash runway challenges.
At the time of this filing, IBRX was trading at $7.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $1.95 to $12.43. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.